You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAluminum hydroxide
Accession NumberDB06723
TypeSmall Molecule
GroupsApproved
Description

Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

Structure
Thumb
Synonyms
Al(OH)3
Aluminiumhydroxid
Aluminum hydroxide
External Identifiers Not Available
Prescription ProductsNot Available
Generic Prescription ProductsNot Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alu-tab Tab 600mgtablet600 mgoral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312001-08-01Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Aluminum Hydroxideliquid320 mg/5mLoralRugby Laboratories, Inc.2005-02-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Aluminum Hydroxidegel320 mg/5mLoralLLC Federal Solutions2013-08-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Derma Granointment.275 g/100gtopicalMc Kesson Medical Surgical2013-11-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dermadroxointment1.2 g/100gtopicalGeritrex Corp2013-01-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dermagran Ointmentointment0.275 %topicalCanadian Medical Supply Inc.1987-12-311996-09-09Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
International Brands
NameCompany
AlternaGelJ&J-Merck
Alu-Cap3M
AmphojelWyeth
Brand mixtures
NameLabellerIngredients
Acid Gone AntacidMajor Pharmaceuticals
Acid Gone Antacid Extra StrengthMajor Pharmaceuticals
Acidex Tc Oral SuspensionGen Drug Company Ltd.
Advanced Antacid CherryMc Kesson
Ahc Premium Intense Contour BalmCarver Korea Co.,Ltd
Alka Phenyl TabDuchesnay Inc
Alka Phenylbutazone TabPro Doc Limitee
AlmaconeRugby Laboratories
Almacone Antacid AntigasRugby Laboratories, Inc.
Almacone Double StrengthRugby Laboratories, Inc.
Aluminum Hydroxide and Magnesium CarbonateSimpex Pharma Pvt. Ltd
Aluminum Hydroxide, Magnesium Hydroxide, SimethiconeLLC Federal Solutions
AlumoxGuardian Drug Company
Amphojel 500 SuspensionAxcan Pharma Inc
AntacidWalgreen Company
Antacid - Alumina and Magnesia Oral Suspension USPD.C. Labs Limited
Antacid and AntigasRij Pharmaceutical Corporation
Antacid Anti-gasCVS
Antacid AntigasSelect Brand
Antacid Antigas Maximum StrengthSelect Brand
Antacid Antigas Maximum Strength MintCVS
Antacid Cherry FlavoredRij Pharmaceutical Corporation
Antacid Double StrengthRij Pharmaceutical Corporation
Antacid Extra StrengthRite Aid Corporation
Antacid Liquid Max Strength CherryCVS
Antacid Liquid MintCVS
Antacid Magnesia and AluminaStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Antacid Maximum StrengthMeijer Distribution Inc
Antacid MintSelect Brand
Antacid Mint FlavoredRij Pharmaceutical Corporation
Antacid Plus Gas ReliefSafeway
Antacid Plus Gas Relief Regular StrengthSafeway
Antacid Regular StrengthKroger Company
Antacid SupremeCVS
Antacid Supreme CherryAaron Industries, Inc.
Antacid SusKsl Pharmaceuticals
Antiacide SusProduits Marc O (1987) Inc., Division Of Technilab Inc.
C2 Buffered TabWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.
C2 Buffered With Codeine TabWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.
Careone AntacidAmerican Sales Company
Careone Antacid Regular StrengthAmerican Sales Company
Careone Liquid AntacidAmerican Sales Company
Centra Acid-susTherapex Division De E Z Em Canada Inc
Conrx ArEagle Distributors,Inc.
Dg Health AntacidDolgencorp, LLC
Diovol EX TabCarter Horner Corp.
EnoBelmora LLC
Equaline AntacidSupervalu Inc
Equaline Antacid Regular StrengthSupervalu Inc
Equate Antacid Extra StrengthWal Mart Stores Inc
Equate Antacid Maximum StrengthWal Mart Stores Inc
Equate Antacid Regular StrengthWal Mart Stores Inc
EstomarolLaboratorios Imperiales, S.A. De C.V.
Exchange Select Antacid Regular StrengthArmy & Air Force Exchange Service
Flanax AntacidBelmora LLC
Foamcoat AntacidGuardian Drug Company
Gasulsol TabHerbes Universelles Inc.
GasvaLes Produits Gerbex Inc.
Gavis-care AntacidGeri Care Pharmaceuticals, Corp
GavisconGlaxo Smith Kline Consumer Healthcare Lp
Gaviscon Extra StrengthGlaxo Smith Kline Consumer Healthcare Lp
Gaviscon Regular StrengthGlaxo Smith Kline Consumer Healthcare Lp
GelusilWell Spring Pharmaceutical Corporation
Gelusil Extra Strength LiqWarner Lambert Canada Inc.
Gelusil Extra Strength TabletsWellspring Pharmaceutical Canada Corp
Gelusil Liquid SusPfizer Canada Inc., Consumer Healthcare Division
Gelusil Maximum StrengthWell Spring Pharmaceutical Corporation
Geri-lanta Antacid AntigasGeri Care Pharmaceuticals, Corp
Geri-lanta Maximum StrengthGeri Care Pharmaceuticals, Corp
Geri-mox Antacid AntigasGeri Care Pharmaceuticals, Corp
Geri-mox Max CherryGeri Care Pharmaceuticals, Corp
Good Neighbor Pharmacy AntacidAmerisource Bergen
Good Sense AntacidL Perrigo Company
Good Sense Antacid Maximum StrengthL Perrigo Company
Good Sense Antacid Regular StrengthL. Perrigo Company
Harris Teeter AntacidHarris Teeter, LLC
Harris Teeter Antacid Maximum StrengthHarris Teeter, LLC
Harris Teeter Antacid Regular StrengthHarris Teeter, LLC
Health Mart AntacidMc Kesson
Healthy Accents AntacidDZA Brands LLC
Healthy Accents MaldroxalDZA Brands LLC
InonSato Pharmaceutical Co., Ltd.
Isa Knox Ageless Serum Makeup Base 10LG Household and Healthcare, Inc.
Isaknox Ageless Serum Blemish BalmLG Household and Healthcare, Inc.
Isaknox Ageless Serum Moist Pearl BaseLG Household and Healthcare, Inc.
Leader Antacid Extra StrengthCardinal Health
Leader Antacid Maximum StrengthCardinal Health
Leader Antacid Regular StrengthCardinal Health
Leader Antacidregular Strength Regular StrengthREMEDYREPACK INC.
Maalox Advanced Maximum Strength CherryNovartis Consumer Health, Inc
Maalox Advanced Maximum Strength MintNovartis Consumer Health, Inc
Maalox Advanced Maximum Strength Wild BerryNovartis Consumer Health, Inc
Maalox Advanced Regular Strength MintNovartis Consumer Health, Inc
Maalox AntacidPhysicians Total Care, Inc.
Maalox SuspensionNovartis Consumer Health Canada Inc.
Maalox TabletRhone Poulenc Rorer Consumer Inc.
Maalox TabletsNovartis Consumer Health Canada Inc.
Maalox Tablets Cherry FlavourCiba Self Medication
Maalox Tablets Mint FlavourCiba Self Medication
Maalox Tc SuspensionRhone Poulenc Rorer Consumer Inc.
Maalox Tc TabletRhone Poulenc Rorer Consumer Inc.
Mag-ALCardinal Health
Mag-AL LiquidPharmaceutical Associates, Inc.
Mag-AL PlusPharmaceutical Associates, Inc.
Mag-AL Plus XsPharmaceutical Associates, Inc.
Maximum Strength AntacidMc Kesson
Maximum Strength Antacid Anti GasPublix Super Markets Inc
Medique Alamag PlusUnifirst First Aid Corporation
Mi-acid Maximum StrengthMAJOR Pharmaceuticals Inc.
Mi-acid Regular StrengthMAJOR Pharmaceuticals Inc.
MintoxMAJOR Pharmaceuticals Inc.
Mintox Maximum StrengthMAJOR Pharmaceuticals Inc.
Mintox Plus TabsMajor Pharmaceuticals
Mylanta Plain Liq Double StrengthParke Davis Division, Warner Lambert Canada Inc.
Mylanta Plain Liq Double Strength SusPfizer Canada Inc., Consumer Healthcare Division
Neutralca S SusDesbergers LtÉe, Division Of Technilab Inc.
Neutralca S TabDesbergers LtÉe, Division Of Technilab Inc.
Phenylone Plus TabMedic Laboratory LtÉe
Regular Strength AntacidChain Drug Marketing Association
Regular Strength Antacid Anti GasPublix Super Markets Inc
Rexall Antacid AdvancedDolgencorp Inc
Ri MoxRij Pharmaceutical Corporation
Riginic Antacid LiquidRij Pharmaceutical Corporation
Rulox RegularRugby Laboratories, Inc.
Rx Act Antacid Extra StrengthH E B
Rx Act Antacid Regular StrengthH E B
Signature Care Antacid Plus Gas ReliefSafeway
Smart Sense AntacidKmart Corporation
Sohmed Acid ReducerSOHM Inc.
Sooryehan Onbit Essence Foundation 21LG Household and Healthcare, Inc.
StomaaxTheralab Inc.
Stratuscare Antacid and AntigasStratus Pharamceuticals
Stratuscare Antacid and Antigas Regular StrengthStratus Pharmaceuticals
Sunmark AntacidMc Kesson
Sunmark Antacid Extra StrengthMc Kesson
Sunmark Antacid Maximum StrengthMc Kesson
Sunmark Antacid Maximum Strength CherryMc Kesson
Topcare AntacidTopco Associates LLC
Topcare Antacid Maximum StrengthTopco Associates LLC
Topcare Antacid Plus Anti GasTopco Associates LLC
Topcare Antacid Regular StrengthTopco Associates LLC
Univol SuspensionCarter Horner Corp.
Up and Up Antacid Anti Gas Regular StrengthTarget Corporation
SaltsNot Available
Categories
UNII5QB0T2IUN0
CAS numberNot Available
WeightAverage: 78.0036
Monoisotopic: 77.989757403
Chemical FormulaAlH3O3
InChI KeyInChIKey=WNROFYMDJYEPJX-UHFFFAOYSA-K
InChI
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
IUPAC Name
aluminium(3+) ion trihydroxide
SMILES
[OH-].[OH-].[OH-].[Al+3]
Taxonomy
DescriptionThis compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
KingdomInorganic compounds
Super ClassMixed metal/non-metal compounds
ClassPost-transition metal oxoanionic compounds
Sub ClassPost-transition metal hydroxides
Direct ParentPost-transition metal hydroxides
Alternative Parents
Substituents
  • Post-transition metal hydroxide
  • Inorganic post-transition metal salt
  • Inorganic hydride
  • Inorganic oxide
  • Inorganic salt
  • Acyclic compound
Molecular FrameworkAcyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of heartburn and acid indigestion.
PharmacodynamicsGastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.
Mechanism of actionAluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
AbsorptionApproximately 17-30% of the aluminum chloride formed is absorbed.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Not metabolized.

Route of eliminationAbsorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5922
Blood Brain Barrier+0.8181
Caco-2 permeable-0.5094
P-glycoprotein substrateNon-substrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.9892
P-glycoprotein inhibitor IINon-inhibitor0.9783
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.8206
CYP450 1A2 substrateNon-inhibitor0.9291
CYP450 2C9 inhibitorNon-inhibitor0.9148
CYP450 2D6 inhibitorNon-inhibitor0.9584
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.9672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9578
Ames testNon AMES toxic0.8393
CarcinogenicityCarcinogens 0.5918
BiodegradationReady biodegradable0.81
Rat acute toxicity1.7247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9592
hERG inhibition (predictor II)Non-inhibitor0.9742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral600 mg
Geloral320 mg/5mL
Liquidoral320 mg/5mL
Ointmenttopical.275 g/100g
Ointmenttopical1.2 g/100g
Ointmenttopical0.275 %
Solutionoral
Powderoral
Tablet, chewableoral
Tabletoral
Granuleoral
Creamtopical
Liquidtopical
Liquidoral
Suspensionoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Richard H. Goheen, William A. Nigro, Paul J. The, “Process for producing aluminum hydroxide of improved whiteness.” U.S. Patent US4915930, issued November, 1933.

US4915930
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 56:04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcepromazineAluminum hydroxide can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlendronateThe serum concentration of Alendronate can be decreased when it is combined with Aluminum hydroxide.
AlfacalcidolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol.
AllopurinolAluminum hydroxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmphetamineAluminum hydroxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AtazanavirAluminum hydroxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.
BenzphetamineAluminum hydroxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
BiotinAluminum hydroxide can cause a decrease in the absorption of Biotin resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aluminum hydroxide.
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Aluminum hydroxide.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Aluminum hydroxide.
BudesonideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.
CalcitriolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Calcitriol.
Calcium citrateCalcium citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.
CathinoneAluminum hydroxide may decrease the excretion rate of Cathinone which could result in a lower serum level and potentially a reduction in efficacy.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Aluminum hydroxide.
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Aluminum hydroxide.
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Aluminum hydroxide.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Aluminum hydroxide.
ChlorpromazineAluminum hydroxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CholecalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Cholecalciferol.
Cholic AcidAluminum hydroxide can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinAluminum hydroxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Aluminum hydroxide.
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Aluminum hydroxide.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Aluminum hydroxide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Aluminum hydroxide.
DasatinibAluminum hydroxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferasiroxThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Aluminum hydroxide.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Aluminum hydroxide.
DemeclocyclineAluminum hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Aluminum hydroxide.
DexmethylphenidateAluminum hydroxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineAluminum hydroxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
DihydrotachysterolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Dihydrotachysterol.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Aluminum hydroxide.
DoxercalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Doxercalciferol.
DoxycyclineAluminum hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Aluminum hydroxide.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Aluminum hydroxide.
ErgocalciferolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Ergocalciferol.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Aluminum hydroxide.
EthambutolAluminum hydroxide can cause a decrease in the absorption of Ethambutol resulting in a reduced serum concentration and potentially a decrease in efficacy.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Aluminum hydroxide.
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.
FluphenazineAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Aluminum hydroxide.
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Aluminum hydroxide.
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Aluminum hydroxide.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Aluminum hydroxide.
GemifloxacinAluminum hydroxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Aluminum hydroxide.
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Aluminum hydroxide.
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Aluminum hydroxide.
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.
Iron DextranAluminum hydroxide can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsoniazidAluminum hydroxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Aluminum hydroxide.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Aluminum hydroxide.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Aluminum hydroxide.
LevofloxacinAluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Aluminum hydroxide.
LisdexamfetamineAluminum hydroxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Aluminum hydroxide.
Magnesium citrateMagnesium citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
MequitazineAluminum hydroxide can cause a decrease in the absorption of Mequitazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Aluminum hydroxide.
MethamphetamineAluminum hydroxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineAluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethylphenidateAluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.
MinocyclineAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
MisoprostolThe risk or severity of adverse effects can be increased when Aluminum hydroxide is combined with Misoprostol.
MoxifloxacinAluminum hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetilAluminum hydroxide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acidAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.
NorfloxacinAluminum hydroxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
OfloxacinAluminum hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
OxytetracyclineAluminum hydroxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ParicalcitolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Aluminum hydroxide.
PerphenazineAluminum hydroxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhendimetrazineAluminum hydroxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
PhentermineAluminum hydroxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
PipotiazineAluminum hydroxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Aluminum hydroxide.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Aluminum hydroxide.
Potassium CitratePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Aluminum hydroxide.
ProchlorperazineAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PromazineAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
QuinidineAluminum hydroxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Aluminum hydroxide.
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Aluminum hydroxide.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Aluminum hydroxide.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Aluminum hydroxide.
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Aluminum hydroxide.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Aluminum hydroxide.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Aluminum hydroxide.
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.
SparfloxacinAluminum hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Aluminum hydroxide.
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Aluminum hydroxide.
TetracyclineAluminum hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ThioridazineAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Aluminum hydroxide.
TriethylenetetramineAluminum hydroxide can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TrifluoperazineAluminum hydroxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ursodeoxycholic acidThe serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide.
Vitamin CVitamin C can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on August 09, 2010 11:11 / Updated on September 16, 2013 18:04